Buckinghamshire CCG partner with Medacy to provide Warfarin to NOAC service

Medacy are delighted to announce that we have been chosen by Buckinghamshire CCG to provide a Warfarin to NOAC service. The service is a key risk minimisation service during the COVID-19 Pandemic.

Decreasing Risk

NHS England has identified supporting patients who need regular monitoring as a particular challenge for practices/hospital performing the monitoring. Patients who are attending either the GP Practice or Hospital for monitoring are also being exposed to increased risk from COVID-19. Medacy’s Pharmacist-led Clinical Service offer a solution that can be mobilised quickly to support the anticoagulation service, practices, patients and practitioners. I’m proud to say that the service is now live and supporting patients. If you would to discuss how Medacy can support your practice, PCN or CCG with a Warfarin to NOAC project please call our Operation Director Caroline on 07732 919225, email caroline@medacy.co.uk or click on the Messenger Icon at the bottom right hand side of the screen

Medacy offer a range of clinical services that can be offered at practice, PCN, GP federation of CCG level. During the pandemic the two most popular services have been around setting up or developing Electronic Repeat Dispensing for practices, long term condition support, support for DMARD patients and Warfarin to NOAC programmes.

So why choose Medacy?

At Medacy we are committed to fully realising the potential of clinical pharmacists. Whether the projects are based in community pharmacies, GP practices, hospitals of a Medacy Clinical Hubs, pharmacists can fundamentally change patient care.

Medacy Clinical Hub

Buckinghamshire CCG (Bucks CCG) have been working alongside Medacy with GP Federation Medicas, North Bucks PCN and Phoenix Healthcare Services since October to deliver a project for patients with Rheumatoid Arthritis. It has been our view that the Medacy Clinical Hubs model is ideally suited to supporting patients with long term conditions due to to the flexibility of the model. This evolution into Warfarin to NOAC work is a prime example of that